The first COVID-19 vaccine to be tested outside of the USA, and only the third vaccine clinical trial in the world, will be conducted by Australia's largest Phase 1 clinical trials specialist Nucleus Network.

As part of the urgent global race to develop a vaccine to tackle the Coronavirus COVID-19 outbreak, Nucleus is due to commence Phase 1 testing for the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, at its Melbourne and Brisbane clinics within the coming weeks.

The Phase 1 trial of NVX-CoV2373 is expected to begin in mid-May with preliminary immunogenicity and safety results in July.

The scale and absolute commitment to the highest standards make Nucleus the ideal partner in the rapid development of the vaccine for COVID-19.